Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

Leading oncology experts to discuss management of hematological malignancies

Leading oncology experts to discuss management of hematological malignancies

Amgen announces results of Phase 3 head-to-head trial evaluating denosumab versus Zometa

Amgen announces results of Phase 3 head-to-head trial evaluating denosumab versus Zometa

Investigative drug hampers the survival of non-Hodgkin lymphoma cells

Investigative drug hampers the survival of non-Hodgkin lymphoma cells

Amgen announces results of Phase 3 trial in the treatment of bone metastases

Amgen announces results of Phase 3 trial in the treatment of bone metastases

Multiple Myeloma Research Foundation focuses on effective cancer treatment

Multiple Myeloma Research Foundation focuses on effective cancer treatment

Millennium's sNDA for VELCADE granted priority review by the FDA

Millennium's sNDA for VELCADE granted priority review by the FDA

Griffin Securities' report features stem cell hypothesis of cancer

Griffin Securities' report features stem cell hypothesis of cancer

Amgen to present its four Phase 3 clinical trial results

Amgen to present its four Phase 3 clinical trial results

FDA provides Orphan-Drug designation for Keryx' KRX-0401 to treat multiple myeloma

FDA provides Orphan-Drug designation for Keryx' KRX-0401 to treat multiple myeloma

Keryx Biopharmaceuticals receives orphan-drug designation for a multiple myeloma drug

Keryx Biopharmaceuticals receives orphan-drug designation for a multiple myeloma drug

Loyola University receives funds to renovate bone marrow transplant unit

Loyola University receives funds to renovate bone marrow transplant unit

Results from Keryx' KRX-0401 Phase 2 study to be presented at the International Kidney Cancer Symposium

Results from Keryx' KRX-0401 Phase 2 study to be presented at the International Kidney Cancer Symposium

Celldex commences dosing patients in Phase 1/2 study of its CDX-1401 vaccine candidate

Celldex commences dosing patients in Phase 1/2 study of its CDX-1401 vaccine candidate

Ascent Therapeutics demonstrates Pepducin efficacy

Ascent Therapeutics demonstrates Pepducin efficacy

FDA approves Supplemental New Drug Application for DOXIL

FDA approves Supplemental New Drug Application for DOXIL

Roche Group and ImmunoCellular Therapeutics sign research agreement regarding ICT-69 antibody

Roche Group and ImmunoCellular Therapeutics sign research agreement regarding ICT-69 antibody

Five Clinical Research Units established

Five Clinical Research Units established

Germany’s BMBF awards NOXXON grant for developing Spiegelmer NOX-A12

Germany’s BMBF awards NOXXON grant for developing Spiegelmer NOX-A12

Gloucester’s romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee

Gloucester’s romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee